GUSTO-IV ACS ABCIXIMAB 24 H 2001

A randomised clinical trial investigating the effect of Abciximab versus placebo in

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>Abciximab 250µg/kg bolus + 0·125µg/kg/min infusion (maximum 0·10µg/min) for 24 h</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Control treatment</th>
<th>placebo</th>
</tr>
</thead>
</table>

Concomittant treatments - 

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>-</th>
</tr>
</thead>
</table>

Inclusion criteria - 

Exclusion criteria - 

3 Methods

<table>
<thead>
<tr>
<th>Blinding</th>
<th>-</th>
</tr>
</thead>
</table>

Design - 

Centers - 

Geographical area - 

<table>
<thead>
<tr>
<th>Sample size</th>
<th>5188 (2590 / 2598)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ArretTrt1</th>
<th>-</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ArretTrt0</th>
<th>-</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>PeriodInclusion</th>
<th>-</th>
</tr>
</thead>
</table>

Hypothese - 

Downloaded from www.trialresultscenter.org
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke (fatal non fatal)</td>
<td>18/2590</td>
<td>16/2598</td>
<td>1.13</td>
<td>[0.57; 2.22]</td>
</tr>
<tr>
<td>Death or myocardial infarction at 5 days</td>
<td>83/2590</td>
<td>97/2598</td>
<td>0.86</td>
<td>[0.64; 1.16]</td>
</tr>
<tr>
<td>Death or myocardial infarction at 30 days</td>
<td>212/2590</td>
<td>209/2598</td>
<td>1.02</td>
<td>[0.83; 1.24]</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>4/2590</td>
<td>1/2598</td>
<td>4.01</td>
<td>[0.45; 35.92]</td>
</tr>
<tr>
<td>Major bleed</td>
<td>123/2590</td>
<td>73/2598</td>
<td>1.69</td>
<td>[1.26; 2.27]</td>
</tr>
</tbody>
</table>

5 References


6 Comments